Drug Trial Radar · NCT05043610
MSCs for Prevention of MI-induced HF
Last checked: Nov 20, 2026Latest source record: Nov 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
420
Actual
Start
Sep 15, 2021
Primary completion
Nov 1, 2024
Study completion Nov 1, 2024
Sponsor
- Lead sponsor
- Shiraz University of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute for Medical Research and Development
- First posted
- Sep 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Results from recent clinical trials on bone marrow mononuclear cell (BM-MNC) transplantation show that this intervention can help reduce the incidence of heart failure (HF) after acute myocardial infarction (AMI). However, no study has evaluated the effect of the transplantation of mesenchymal stem cells (MSCs) on a clinical endpoint such as HF. This single-blinded, randomized, multicenter trial aims to establish whether the intracoronary infusion of umbilical cord-derived Wharton's jelly MSCs (WJ-MSCs) helps prevent HF development after AMI. The study will enroll 240 patients 3 to 7 days following an AMI treated with primary percutaneous coronary intervention (PPCI). Only patients aged below 65 years with impaired LV function (LVEF \< 40%) will be included. Patients will be randomized to receive either a single intracoronary infusion of WJ-MSCs or standard care. The primary outcome of this study is the assessment of HF development during long-term follow-up (three years). Since the efficacy of MSCs is higher than BM-MNCs after AMI in the improvement of LVEF, it would be probable that these cells may have a better clinical effect as well. However, no study has evaluated the impact of the transplantation of MSCs on a clinical endpoint such as HF. This study will help determine whether or not the infusion of intracoronary WJ-MSCs in AMI patients with impaired LVEF would prevent HF development and future adverse events.
Conditions
- Myocardial Infarction, Acute
- Myocardial Infarction First
- Myocardial Infarction, Anterior Wall
- Cardiac Remodeling, Ventricular
- STEMI
- Regenerative Medicine
- Heart Failure
Interventions
Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs)Biological
cGMP grade WJ-MSCs. 10\^7 WJ-MSCs will be delivered through the intracoronary route. WJ-MSCs will be infused at a rate of 2.5 ml/min across three portions.
Conventional TreatmentOther
Beta-blocker, angiotensin-converting enzyme (ACE) inhibitor, aldosterone antagonist, aspirin, ticagrelor, statin, and glyceryl trinitrate plus cardiac rehabilitation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Heart FailureTime frame: Checked at three years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Al-Zahra Heart Hospital, Shiraz University of Medical Sciences
Shiraz, Fars, Iran
Faghihi Hospital
Shiraz, Fars, Iran
Namazee Hospital
Shiraz, Fars, Iran
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.